Application of ultralow doses of antibodies to interferon-gamma in complex therapy of bacterial infections and prophylaxis of bacterial complications.
Comparative placebo-controlled clinical trials on the efficiency and safety of ultralow doses of antibodies to human IFN-gamma (anaferon pediatric formulation and anaferon) and prophylaxis of bacterial complication showed that administration of these preparations in complex therapy of bacterial infection reduced the incidence of bacterial complications of viral infections and considerably decreased the duration of the main clinical symptoms of the disease.
Tarasov
S A
SA
Materia Medica Holding Research-and-Production Company, Moscow.
Kachanova
M V
MV
Zhavbert
E S
ES
Dugina
Yu L
YL
Epshtein
O I
OI
Sergeeva
S A
SA
D000906:Antibodies / Q000276:immunology* / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy*; D006801:Humans; D007369:Interferon Inducers / Q000627:therapeutic use; D007371:Interferon-gamma / Q000276:immunology*; D016896:Treatment Outcome
D000906:Antibodies; D000998:Antiviral Agents; D007369:Interferon Inducers; D007371:Interferon-gamma